# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from...
Goldman Sachs analyst Chris Shibutani maintains United Therapeutics (NASDAQ:UTHR) with a Neutral and raises the price target...
Oppenheimer analyst Hartaj Singh maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target f...
HC Wainwright & Co. analyst Andrew Fein reiterates United Therapeutics (NASDAQ:UTHR) with a Buy and maintains $300 price...
United Therapeutics impresses with record-breaking Q1 results. Revenue soars 34% Y/Y to $677.7 million, EPS jumps to $6.17. Tyv...
United Therapeutics (NASDAQ:UTHR) reported quarterly earnings of $6.17 per share which beat the analyst consensus estimate of $...